In the Journal of Clinical Investigation, Navdeep Chandel and colleagues from Northwestern University report the effects of a SOD1 pharmacological inhibitor on non-small-cell lung cancer (NSCLC) cells. The inhibitor, called ATN-224, stunted the growth of human NSCLC cells in culture and induced their death. Read more here.
Study mentioned: Glasauer A, et al. Targeting SOD1 reduces experimental non-small-cell lung cancer. J Clin Invest. 2013 Dec 2. [Epub ahead of print] PMID: 24292713
No comments:
Post a Comment